Semaglutide has not been proven to cause blood clots, and the FDA-approved labels for both Ozempic and Wegovy do not include blood clots as a warning. However, a meta-analysis of major clinical trials found a statistically significant increase in deep vein thrombosis (DVT) among semaglutide users compared to controls, raising questions that researchers are still working to answer.
The picture is complicated by the fact that semaglutide also appears to protect the cardiovascular system in other ways. Understanding what the data actually shows, and where the gaps are, can help you put this risk in perspective.
What the Clinical Trial Data Shows
The most cited analysis pooled data from the PIONEER and SUSTAIN trial programs, which together included more than 12,000 semaglutide users and 14,000 controls. That analysis found semaglutide was associated with a 3.66 times higher rate of DVT compared to placebo. DVT is a blood clot that forms in a deep vein, usually in the leg.
A broader meta-analysis looking at the entire class of GLP-1 receptor agonists (the drug category semaglutide belongs to) found a more modest but still notable signal. Across all drugs in the class, users had a 64% higher likelihood of developing DVT, translating to roughly 25 additional DVT events per 10,000 people per year compared to non-users. Importantly, the same analysis found no significant link between these drugs and pulmonary embolism, which is a clot that travels to the lungs and is typically more dangerous.
The overall risk of venous thromboembolism (a term covering both DVT and pulmonary embolism together) showed an upward trend but did not reach statistical significance, meaning researchers can’t rule out that the combined result was due to chance.
Why the FDA Label Doesn’t Mention Clots
The FDA-approved prescribing information for Wegovy lists warnings for pancreatitis, gallbladder disease, kidney injury, hypersensitivity reactions, heart rate increases, and suicidal ideation, among others. Blood clots are not included. This likely reflects the fact that while the DVT signal exists in pooled analyses, it hasn’t been large enough or consistent enough across individual trials to trigger a formal label change.
The European Medicines Agency has not flagged blood clots as a specific concern either, though its safety committee is currently reviewing semaglutide in connection with a separate vascular issue: a rare eye condition called non-arteritic anterior ischemic optic neuropathy, which involves reduced blood flow to the optic nerve.
Dehydration as a Possible Explanation
One leading theory connects the DVT signal not to a direct clotting effect of semaglutide but to its well-known gastrointestinal side effects. Nausea, vomiting, and diarrhea are the most common complaints among semaglutide users. The same pooled analysis that identified the DVT risk also found a 166% increase in diarrhea cases. Persistent diarrhea or vomiting can lead to dehydration, which thickens the blood and makes clots more likely to form.
This isn’t unique to semaglutide. Any condition or medication that causes significant fluid loss can raise clot risk through the same mechanism. If you’re taking semaglutide and experiencing frequent GI symptoms, staying well-hydrated becomes especially important. Recognizing the signs of dehydration (dark urine, dizziness, dry mouth, fatigue) is a practical step you can take to reduce this indirect risk.
How Semaglutide Affects Platelets Directly
The biology here is surprisingly contradictory. Platelets, the tiny blood cells that clump together to form clots, actually have receptors for GLP-1, the hormone that semaglutide mimics. When those receptors are activated, platelet clumping appears to decrease, not increase.
In controlled human experiments using liraglutide (a closely related drug in the same class), two weeks of treatment reduced the clumping response of platelets by 54%. This effect occurred before any weight loss, suggesting it’s a direct action of the drug on the platelets themselves rather than a downstream benefit of losing weight. Researchers confirmed this by using a chemical that blocks the GLP-1 receptor, which reversed the anti-clumping effect.
There’s also early evidence that GLP-1 receptor agonists may suppress a molecule called PAI-1, which normally slows down the body’s ability to dissolve clots. Lower PAI-1 activity would theoretically make your body better at clearing clots before they cause problems. These mechanisms suggest the drug itself may have anti-clotting properties, which makes the DVT signal in trials harder to explain through direct pharmacology alone and lends more weight to the dehydration hypothesis.
The Bigger Cardiovascular Picture
Whatever the DVT signal means, it exists alongside strong evidence that semaglutide protects against the most common and deadly cardiovascular events. The SELECT trial, which studied semaglutide in people with obesity and existing heart disease, found a 20% reduction in the combined risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke over about 3.3 years of follow-up. The reductions were substantial: a 53% drop in cardiovascular death and a 43% drop in nonfatal heart attacks.
This creates a complex risk-benefit picture. The drug appears to significantly reduce arterial events (heart attacks and strokes, which involve clots in arteries) while possibly increasing venous events (DVT, which involves clots in veins). Arterial and venous clots form through somewhat different mechanisms, so it’s biologically plausible for a drug to influence them in opposite directions.
Who Should Pay Attention
If you already have risk factors for DVT, the signal in the data is worth discussing with your prescriber. Known DVT risk factors include a personal or family history of blood clots, prolonged immobility (long flights, bed rest after surgery), smoking, use of estrogen-containing birth control or hormone therapy, and certain inherited clotting disorders. Obesity itself is a DVT risk factor, which complicates the picture further since many people taking semaglutide have obesity.
For people without these additional risk factors, the absolute numbers remain small. Even in the broader GLP-1 receptor agonist analysis, the excess risk amounted to about 25 additional DVT cases per 10,000 people per year. That’s a meaningful increase in relative terms but a low probability for any individual. Staying hydrated, staying physically active, and knowing the symptoms of DVT (swelling, pain, or warmth in one leg, often the calf) are reasonable precautions for anyone on the medication.